Syndax Pharmaceuticals

#GivingTuesday is only one week away! This year, we’re proud to highlight Cancer Hope Network (CHN), whose mission is to provide one-on-one peer mentorship support for adults impacted by cancer. By providing emotional support, practical advice and effective coping methods, CHN’s goal is to inspire hope and to help create a world in which no one faces cancer alone. Learn more: https://lnkd.in/d-i3eEy5

Recently, the Syndax team attended the 2024 American Conference on Pharmacometrics (ACoP) in Phoenix, AZ, where we shared two posters exploring population pharmacokinetic (PopPK) and physiologically based pharmacokinetic (PBPK) models of revumenib. This was an incredible opportunity to share insights with other industry leaders dedicated to advancing the discipline of pharmacometrics. Learn more: https://lnkd.in/gtDkN9hQ #ACoP2024 #ISoP

#NewsAlert: We are thrilled to announce a major milestone for Syndax. The U.S. Food and Drug Administration (FDA) has now approved the first and only therapy for relapsed or refractory acute leukemia with a KMT2A translocation. We would like to extend our heartfelt gratitude to the clinicians, investigators, Syndax employees, and patients who made this achievement possible. Learn more by reading our press release and tuning in to our live webcast today at 6:00 p.m. ET: https://lnkd.in/gWBzGqqp A replay will be available after the call. ? #FDAApproval #WeFlyHigherTogether

#NewsAlert: Today, we shared positive topline results from the R/R mNPM1 acute myeloid leukemia (#AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib. These data underscore the long-term potential of revumenib, which has shown compelling results in both KMT2A-rearranged and mutant NPM1 acute leukemias. We would like to extend our heartfelt gratitude to all trial participants, investigators, and Syndax employees who made this trial possible! Learn more: https://lnkd.in/gTumRaWg Or join us on a conference call with management today at 8:00 a.m. ET: https://lnkd.in/gU8RDqyU

On Veterans Day, we celebrate, honor and remember the individuals who made tremendous sacrifices in service of our nation. Today, we recognize our Vice President of Commercial Operations Excellence, Andrew, who served in the U.S. Army for more than six years, where he learned the power of collaboration, trust and communication. We thank him and other veterans for their service! Know a veteran who wants to join us on our mission to reimagine cancer care? Learn more about open positions below: https://lnkd.in/gFDk_VhU #WeFlyHigherTogether

Join?our growing regulatory team, and be empowered to do your best work: syndax.com/careers #Biotech #Regulatory #Jobs

#NewsAlert: Today, we reported our third quarter 2024 financial results and provided a business update. This has been a transformative period for Syndax with the announcement of our first FDA approval for Niktimvo? (axatilimab-csfr) in partnership with Incyte. We have a very exciting quarter ahead with the anticipated FDA approval and U.S. launch of revumenib for adults and pediatrics with R/R KMT2Ar acute leukemia, as well as the expected readout of topline pivotal data from patients with R/R mNPM1 AML. Learn more about Syndax, including our recent announcements on accepted ASH abstracts and $350 million royalty agreement for Niktimvo, by reading our full release and joining us on our conference call today at 4:30 p.m. ET: https://lnkd.in/g4PhwF-W A replay will be available after the call.

We’re pleased to announce that new data from multiple trials across our clinical program for revumenib will be featured in three oral sessions during the 66th American Society of Hematology #ASH24 Annual Meeting. Additionally, we will be presenting new data from a secondary analysis of overall and organ-specific responses from the pivotal Phase 2 AGAVE-201 trial of axatilimab. These data reinforce our confidence in the potential of our pipeline, and we look forward to continuing to rapidly advance the development of both programs across the continuum of treatment. More details are available below:? https://lnkd.in/guWPP7JP https://lnkd.in/gugkJGNu

#NewsAlert: Today, we are excited to announce that we entered into a $350 million royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo? (axatilimab-csfr). Through this transaction, we significantly strengthened our balance sheet, funding us through profitability and supporting our Niktimvo and revumenib commercialization and development efforts, while ensuring we participate in the profits from Niktimvo and retain the upside of its future growth. Learn more by reading the press release: https://lnkd.in/g5-7uhwr

November marks National Family Caregivers Month, a time to recognize and honor the dedication and selfless efforts of family caregivers nationwide. This is also an opportunity to raise awareness of caregiving issues, educate communities and increase support for caregivers. This month, we’re proud to highlight Elephants and Tea, an organization dedicated to building community and support for adolescent and young adult (AYA) patients, survivors and caregivers through wellness, storytelling, education and research. Learn more: https://lnkd.in/ewujGPGM